Zymeworks authorizes $200 million share repurchase program
The second 2026 program authorizes up to $200.0 million in repurchases through 2028, with approximately $140.0 million expected to be spent.
See the latest news and media coverage for Zymeworks. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global biotechnology company developing medicines and managing licensed assets
zymeworks.comLast updated
In short: Zymeworks authorized a $200 million buyback, raised guidance, completed its Theravance acquisition and advanced a Roche partnership.
The second 2026 program authorizes up to $200.0 million in repurchases through 2028, with approximately $140.0 million expected to be spent.
Total revenue reaches $256.5 million on a $250 million Jazz milestone, net income is $173.7 million, and the Theravance Biopharma acquisition closes.
Zymeworks grants exclusive rights to Roche for the DLL3-targeting candidate ZW209, receiving $55 million upfront and up to $718 million in potential milestones.
Theravance becomes a subsidiary while CVRs are issued to shareholders. Senior secured notes with an 8.25% interest rate mature in 2036.
Zymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases...
(previously between $278 million and $292 million) and an Adjusted EBITDA range of $176 million to $190 million (previously between $114 million and $128 million...
Zymeworks said on Friday Roche has gained rights to develop and commercialize its experimental lung...
Acquisition diversifies durable cash flows and advances Zymeworks' strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI ® expected...
Track Zymeworks and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Zymeworks and other trending companies.